CLL Panel
Chromoprobe Multiprobe CLL Panel Protocole
The Chromoprobe Multiprobe Leukaemia Panels have been designed to provide as much information about as many chromosomal rearrangements as possible for each of the Luekaemias targeted on slide in a single hybridisation experiment.
o Fish detects rearrangements in 72% of patients. Conventional Cytogenetics successful in 31%
o Detects Balanced chromosome rearrangements
o Interphase analysis:no culturing necessary
o Eight chromosome rearrangements detected simultaneously in a single FISH reaction on a single microscope slide
o Detection easily automated: signals show as spots
o Diagnosis provides prognosis
o Diagnosis directs therapy

Eight chromosome rearrangements detected simultaneously in a single FISH :
Visualized the CLL Panel

Knowledge of the precise rearrangement involved has been shown to have important implications for the prognosis for the patient and can thus provide vital diagnostic and patient management information. These devices have therefore been designed to help fill the gap between diagnosis and prognosis, helping, therefore to direct the treatment of these important and relatively common diseases.
Chronic lymphocytic leukaemia is the most common of the B-cell lineage lymphoproliferative disorders, accounting for about 30% of all cases in the USA and Europe, though it is extremely rare in the orient. Where the disease is prevalent, it occurs almost exclusively in the middle-aged and elderly and is therefore rarely observed in children. The disease is found in both B- and T-cell lineages, though 95% of cases are of B-cell origin. Until relatively recently, study in to the chromosome rearrangements that may lead to CLL had been hampered by the low spontaneous mitotic rate of these tissues.
The introduction of B-cell mitogens into the field improved the number of cells analysable by conventional cytogenetics and increased the number of rearrangements implicated in the disease. Trisomy 12, deletions of 13q and the 14q marker chromosomes were the first to be detected, though it was not until the introduction FISH in the study of Leukaemia that the true incidence and therefore relevance of these rearrangements began to become clear. Further molecular genetic studies in recent years have increased the numbers of chromosome rearrangements involved in CLL, showing that deletions of 6q (MYB), 17p (p53) and 11q (ATM) are also important.

ALL Panel
New version of the Chromoprobe Multiprobe ALL Panel available !
The Chromoprobe Multiprobe ALL Panel has been designed to detect multiple rearrangements that occur primarily in B-cell lineage ALL in addition to several T-lineage markers. The panel can be used to rapidly determine genotype in leukaemia patients and aid in prognosis and treatment.
o Picks up translocations involving MLL gene which occur in 85% of paediatric ALL
o Detects TEL(ETV6)/AML1 found in 21% of paediatric cases
o Detects Aneuploidy which occurs in 30% of ALL cases. the number and identity of additional chromosomes is of significant prognostic value
o E2A probes for t(1,19) detect 20% of patients undetectable by conventional tests
o IGH and MYC identifies patients with Burkitt Lymphoma-like ALL
o Rapid method and low cost per probe
Eight chromosome abnormalities detected simultaneously in a single FISH :
Visualized the CLL Panel

Knowledge of the precise rearrangement involved in the disorder has been shown to have important implications for prognosis of the patient and can thus provide vital diagnostic and patient management information. For ALL the importance of karyotype as a predictor of clinical outcome has been known since 1978; this has led to Cytogenetics, and more recently FISH, to be important aspects of ALL treatment trials. This correlation supports the need for an ALL panel to help fill the gap between diagnosis and prognosis. In so doing, it may help to direct and manage the treatment of this important and relatively common disease.
Acute Lymphoblastic Leukaemia is most common in the young, especially in childhood. It represents 23% of cancer diagnoses among children younger than 15 years of age and occurs at an annual rate of approximately 31 per million. In young adults the median age is around 30 whilst in children the incidence is higher between the ages of 2 to 5.
The disease is classified using the French-American-British (FAB) classification system based in the morphological characteristics of the immature lymphoid cells that accumulate in the bone marrow and peripheral blood. The system classifies cells as either L1, L2 or L3 and each one has a series of
characteristic chromosome rearrangements associated with them.
Cytocell's Chromoprobe Multiprobe ALL panel has been designed to detect rearrangements that occur primarily in B-cell lineage ALL, though some T-lineage markers have been included. In addition, in common with the CLL panel, the panel strategy has been developed to give the maximum amount of information from cells at interphase and in some cases is capable of detecting chromosome rearrangements that are undetectable using standard cytocgenetics.